Review summary
Historical dates
April 5, 1856 – November 14, 1915Synthetic DOB
1967-04-05Index visit
2026-05-04 at age 59Synthetic MRN
HR-NI017-SYNTeaching objective: Recognize severe hypertension with kidney damage in a busy, hard-working adult, separate it from a hypertensive emergency, and manage hypertensive chronic kidney disease stage G3b A3 with maximum-dose renin-angiotensin blockade, an SGLT2 inhibitor, combination blood pressure therapy, and laboratory monitoring on the CMID schedule, while avoiding the biased attributions recorded in 1915.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| April 5, 1856 | Born into slavery on the Burroughs plantation, Franklin County, Virginia; the exact date is uncertain. | CLM-0001, CLM-0002 |
| 1865 | Emancipated; moved with his family to Malden, West Virginia. | CLM-0003 |
| 1876 | Mother, Jane, died in Malden. | CLM-0003 |
| July 4, 1881 | Opened Tuskegee Institute. | CLM-0004 |
| 1911 | Beaten in New York City; head lacerations and a torn ear. | CLM-0005 |
| March 1915 | Sponsored National Negro Health Week. | CLM-0004 |
| November 2, 1915 | Admitted to the Rockefeller Institute hospital; blood pressure 220/150; Bright's disease diagnosed. | CLM-0006, CLM-0007, CLM-0010 |
| November 14, 1915 | Died at home in Tuskegee, Alabama. | CLM-0008 |
| 2006 | Historical clinicopathological conference attributes his death to malignant hypertension with kidney failure. | CLM-0009 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Booker T. Washington was born into slavery on the James Burroughs plantation in Franklin County, Virginia, in 1856; the National Park Service timeline gives the date as April 5, 1856. | confirmed | Booker T. Washington supports Washington Timeline supports |
| D | Washington wrote in Up from Slavery (1901) that he was not sure of the exact date of his birth and estimated the year as 1858 or 1859; the April 5, 1856 date traces to a report by his brother John after his death and was adopted by the Tuskegee trustees. The exact birth date is uncertain; the case uses the NPS date of April 5, 1856. |
probable | Black B. The Strange Case of Booker T. Washington's Birthday. Contingent Magazine, April 5, 2021 supports |
| D | After emancipation in 1865 Washington moved with his mother, Jane, and his family to Malden, West Virginia, where he worked in the salt and coal mines; a National Park Service release gives his mother's death as 1876. The source gives no cause of death; other accounts give 1874. |
probable | Washington Timeline supports Footprints: Women Who Influenced Booker T. Washington (news release) supports |
| D | Washington opened Tuskegee Institute in Tuskegee, Alabama, on July 4, 1881, at age 25, and led it for the rest of his life; in March 1915 he sponsored National Negro Health Week. | confirmed | Washington Timeline supports Booker T. Washington supports |
| D | In 1911 Washington was beaten in New York City and received two large gashes in his head and a torn ear, recovering without apparent sequelae; he had chronic indigestion, especially when traveling, and spent several days in 1911 at the Battle Creek Sanitarium. From the annotated hospital record published with the 2006 clinicopathological conference. |
probable | The Death of Booker T. Washington (site bulletin) supports |
| D | When Washington was admitted to the Rockefeller Institute hospital on November 2, 1915, his blood pressure was 220/150. He reported palpitations two weeks earlier, tiring quickly, frontal headaches one or two days out of every eight or nine, and slower thinking; the record also notes weight loss, failing vision, frequent urination, and avid thirst. The documented anchor for the synthetic hypertension and kidney disease episode. |
confirmed | The Death of Booker T. Washington (site bulletin) supports |
| D | In early November 1915, after several months of failing health, Dr. W. A. Bastedo in New York diagnosed Bright's disease, a contemporary term for kidney disease; Dr. Lucas G. Cole at the Rockefeller Institute hospital agreed, and Washington was moved to St. Luke's Hospital. | confirmed | The Death of Booker T. Washington (site bulletin) supports |
| D | Washington traveled home from New York and died at Tuskegee on November 14, 1915, at age 59; the New York Times reported hardening of the arteries as the cause, and the National Park Service attributes his death to conditions related to high blood pressure. Record the death as a fact without graphic detail. |
confirmed | The Death of Booker T. Washington (site bulletin) supports Booker T. Washington supports |
| R | A 2006 historical clinicopathological conference at the University of Maryland School of Medicine reviewed his hospital record and concluded that he presented with malignant hypertension that caused kidney failure. A retrospective diagnosis; the modern problem list uses hypertensive kidney disease without asserting it as historical fact. |
probable | The Death of Booker T. Washington (site bulletin) supports |
| D | A 1915 remark by Dr. Bastedo attributing the death partly to 'racial characteristics' was read by Washington's Chicago physician, Dr. George C. Hall, as implying syphilis; the hospital Wassermann test was negative, and the 2006 review did not support that explanation. Teaching point about biased attribution in medical records; do not repeat the remark without this context. |
confirmed | The Death of Booker T. Washington (site bulletin) supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Severe hypertension with hypertensive kidney disease; synthetic modern diagnosis linked to the documented 1915 blood pressure of 220/150 | active | confirmed | both_with_link | CLM-0006, CLM-0009 |
| S | Chronic kidney disease stage G3b A3 (severely increased albuminuria), attributed to hypertensive nephrosclerosis | active | confirmed | both_with_link | CLM-0007, CLM-0009 |
| S | Hypertensive retinopathy, both eyes, without papilledema | active | confirmed | active | CLM-0006 |
| S | Mild anemia of chronic kidney disease, iron replete; monitor | active | confirmed | active | |
| S | Hyperlipidemia | active | confirmed | active | |
| S | Acute lumbar muscle strain after lifting, resolved without NSAIDs or imaging | resolved | confirmed | active |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2026-05-04 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-05-04 | Potassium [Moles/volume] in Serum or Plasma | 4.4 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-05-04 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 21 mmol/L (low) Reference 22-29 mmol/L |
http://loinc.org · 2028-9 |
| S | 2026-05-04 | Urea nitrogen [Mass/volume] in Serum or Plasma | 34 mg/dL (high) Reference 6-24 mg/dL |
http://loinc.org · 3094-0 |
| S | 2026-05-04 | Creatinine [Mass/volume] in Serum or Plasma | 2.1 mg/dL (high) Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-05-04 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 36 mL/min/1.73 m² (low) Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-05-04 | Glucose [Mass/volume] in Serum or Plasma | 92 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-05-04 | Calcium [Mass/volume] in Serum or Plasma | 9.1 mg/dL Reference 8.6-10.3 mg/dL |
http://loinc.org · 17861-6 |
| S | 2026-05-04 | Phosphate [Mass/volume] in Serum or Plasma | 4.2 mg/dL Reference 2.5-4.5 mg/dL |
http://loinc.org · 2777-1 |
| S | 2026-05-04 | Parathyrin.intact [Mass/volume] in Serum or Plasma | 92 pg/mL (high) Reference 15-65 pg/mL |
http://loinc.org · 2731-8 |
| S | 2026-05-04 | Hemoglobin [Mass/volume] in Blood | 12.6 g/dL (low) Reference 13.2-16.6 g/dL |
http://loinc.org · 718-7 |
| S | 2026-05-04 | Ferritin [Mass/volume] in Serum or Plasma | 210 ng/mL Reference 30-400 ng/mL |
http://loinc.org · 2276-4 |
| S | 2026-05-04 | Iron saturation [Mass Fraction] in Serum or Plasma | 26% Reference 20-50% |
http://loinc.org · 2502-3 |
| S | 2026-05-04 | Thyrotropin [Units/volume] in Serum or Plasma | 1.8 mIU/L Reference 0.45-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 2026-05-04 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.4% Reference <=5.6% |
http://loinc.org · 4548-4 |
| S | 2026-05-04 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 138 mg/dL (high) Reference <=99 mg/dL |
http://loinc.org · 13457-7 |
| S | 2026-05-04 | Albumin/Creatinine [Mass Ratio] in Urine | 820 mg/g (high) Reference <=30 mg/g |
http://loinc.org · 9318-7 |
| S | 2026-05-04 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | http://loinc.org · 44261-6 |
| S | 2026-05-11 | Sodium [Moles/volume] in Serum or Plasma | 138 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-05-11 | Potassium [Moles/volume] in Serum or Plasma | 4.6 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-05-11 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 22 mmol/L Reference 22-29 mmol/L |
http://loinc.org · 2028-9 |
| S | 2026-05-11 | Urea nitrogen [Mass/volume] in Serum or Plasma | 36 mg/dL (high) Reference 6-24 mg/dL |
http://loinc.org · 3094-0 |
| S | 2026-05-11 | Creatinine [Mass/volume] in Serum or Plasma | 2.2 mg/dL (high) Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-05-11 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 34 mL/min/1.73 m² (low) Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-05-11 | Glucose [Mass/volume] in Serum or Plasma | 95 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-06-01 | Sodium [Moles/volume] in Serum or Plasma | 137 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-06-01 | Potassium [Moles/volume] in Serum or Plasma | 4.9 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-06-01 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 22 mmol/L Reference 22-29 mmol/L |
http://loinc.org · 2028-9 |
| S | 2026-06-01 | Urea nitrogen [Mass/volume] in Serum or Plasma | 38 mg/dL (high) Reference 6-24 mg/dL |
http://loinc.org · 3094-0 |
| S | 2026-06-01 | Creatinine [Mass/volume] in Serum or Plasma | 2.4 mg/dL (high) Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-06-01 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 30 mL/min/1.73 m² (low) Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-06-01 | Glucose [Mass/volume] in Serum or Plasma | 94 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-06-29 | Sodium [Moles/volume] in Serum or Plasma | 135 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-06-29 | Potassium [Moles/volume] in Serum or Plasma | 4.3 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-06-29 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23 mmol/L Reference 22-29 mmol/L |
http://loinc.org · 2028-9 |
| S | 2026-06-29 | Urea nitrogen [Mass/volume] in Serum or Plasma | 36 mg/dL (high) Reference 6-24 mg/dL |
http://loinc.org · 3094-0 |
| S | 2026-06-29 | Creatinine [Mass/volume] in Serum or Plasma | 2.4 mg/dL (high) Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-06-29 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 30 mL/min/1.73 m² (low) Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-06-29 | Glucose [Mass/volume] in Serum or Plasma | 96 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-06-29 | Albumin/Creatinine [Mass Ratio] in Urine | 360 mg/g (high) Reference <=30 mg/g |
http://loinc.org · 9318-7 |
| S | 2026-10-26 | Sodium [Moles/volume] in Serum or Plasma | 136 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-10-26 | Potassium [Moles/volume] in Serum or Plasma | 4.5 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-10-26 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23 mmol/L Reference 22-29 mmol/L |
http://loinc.org · 2028-9 |
| S | 2026-10-26 | Urea nitrogen [Mass/volume] in Serum or Plasma | 34 mg/dL (high) Reference 6-24 mg/dL |
http://loinc.org · 3094-0 |
| S | 2026-10-26 | Creatinine [Mass/volume] in Serum or Plasma | 2.3 mg/dL (high) Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-10-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 32 mL/min/1.73 m² (low) Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-10-26 | Glucose [Mass/volume] in Serum or Plasma | 93 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-10-26 | Calcium [Mass/volume] in Serum or Plasma | 9.2 mg/dL Reference 8.6-10.3 mg/dL |
http://loinc.org · 17861-6 |
| S | 2026-10-26 | Phosphate [Mass/volume] in Serum or Plasma | 4 mg/dL Reference 2.5-4.5 mg/dL |
http://loinc.org · 2777-1 |
| S | 2026-10-26 | Parathyrin.intact [Mass/volume] in Serum or Plasma | 78 pg/mL (high) Reference 15-65 pg/mL |
http://loinc.org · 2731-8 |
| S | 2026-10-26 | Hemoglobin [Mass/volume] in Blood | 12.8 g/dL (low) Reference 13.2-16.6 g/dL |
http://loinc.org · 718-7 |
| S | 2026-10-26 | Albumin/Creatinine [Mass Ratio] in Urine | 240 mg/g (high) Reference <=30 mg/g |
http://loinc.org · 9318-7 |
| S | 2026-10-26 | Kidney failure 2-year risk [Likelihood] by KFRE | 6.5% | http://loinc.org · 85624-5 |
| S | 2026-10-26 | Kidney failure 5-year risk [Likelihood] by KFRE | 18.8% | http://loinc.org · 85625-2 |
| S | 2026-10-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | http://loinc.org · 44261-6 |
| S | 2026-05-11 | Left ventricular Ejection fraction | 60% Reference 50-70% |
http://loinc.org · 10230-1 |
| S | 2026-08-10 | Sodium [Moles/volume] in Serum or Plasma | 137 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-08-10 | Potassium [Moles/volume] in Serum or Plasma | 4.7 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-08-10 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23 mmol/L Reference 22-29 mmol/L |
http://loinc.org · 2028-9 |
| S | 2026-08-10 | Urea nitrogen [Mass/volume] in Serum or Plasma | 37 mg/dL (high) Reference 6-24 mg/dL |
http://loinc.org · 3094-0 |
| S | 2026-08-10 | Creatinine [Mass/volume] in Serum or Plasma | 2.4 mg/dL (high) Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-08-10 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 30 mL/min/1.73 m² (low) Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-08-10 | Glucose [Mass/volume] in Serum or Plasma | 94 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-09-21 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | http://loinc.org · 44261-6 |
| S | 2026-09-21 | Total score [AUDIT-C] | 1 | http://loinc.org · 75626-2 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2026-05-04 | Body height | 170 cm | 8302-2 | S |
| 2026-05-04 | Body weight | 71 kg | 29463-7 | S |
| 2026-05-04 | Body mass index (BMI) [Ratio] | 24.6 kg/m2 | 39156-5 | S |
| 2026-05-04 | Systolic blood pressure | 212 mm[Hg] | 8480-6 | S |
| 2026-05-04 | Diastolic blood pressure | 128 mm[Hg] | 8462-4 | S |
| 2026-05-04 | Heart rate | 88 /min | 8867-4 | S |
| 2026-05-04 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-05-04 | Body temperature | 36.8 Cel | 8310-5 | S |
| 2026-05-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-05-11 | Body height | 170 cm | 8302-2 | S |
| 2026-05-11 | Body weight | 71 kg | 29463-7 | S |
| 2026-05-11 | Body mass index (BMI) [Ratio] | 24.6 kg/m2 | 39156-5 | S |
| 2026-05-11 | Systolic blood pressure | 172 mm[Hg] | 8480-6 | S |
| 2026-05-11 | Diastolic blood pressure | 104 mm[Hg] | 8462-4 | S |
| 2026-05-11 | Heart rate | 82 /min | 8867-4 | S |
| 2026-05-11 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-05-11 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-05-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-06-01 | Body height | 170 cm | 8302-2 | S |
| 2026-06-01 | Body weight | 70 kg | 29463-7 | S |
| 2026-06-01 | Body mass index (BMI) [Ratio] | 24.2 kg/m2 | 39156-5 | S |
| 2026-06-01 | Systolic blood pressure | 148 mm[Hg] | 8480-6 | S |
| 2026-06-01 | Diastolic blood pressure | 92 mm[Hg] | 8462-4 | S |
| 2026-06-01 | Heart rate | 78 /min | 8867-4 | S |
| 2026-06-01 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-06-01 | Body temperature | 36.8 Cel | 8310-5 | S |
| 2026-06-01 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-06-29 | Body height | 170 cm | 8302-2 | S |
| 2026-06-29 | Body weight | 70 kg | 29463-7 | S |
| 2026-06-29 | Body mass index (BMI) [Ratio] | 24.2 kg/m2 | 39156-5 | S |
| 2026-06-29 | Systolic blood pressure | 128 mm[Hg] | 8480-6 | S |
| 2026-06-29 | Diastolic blood pressure | 80 mm[Hg] | 8462-4 | S |
| 2026-06-29 | Heart rate | 74 /min | 8867-4 | S |
| 2026-06-29 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-06-29 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-06-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-10-26 | Body height | 170 cm | 8302-2 | S |
| 2026-10-26 | Body weight | 70.5 kg | 29463-7 | S |
| 2026-10-26 | Body mass index (BMI) [Ratio] | 24.4 kg/m2 | 39156-5 | S |
| 2026-10-26 | Systolic blood pressure | 118 mm[Hg] | 8480-6 | S |
| 2026-10-26 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-10-26 | Heart rate | 72 /min | 8867-4 | S |
| 2026-10-26 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-10-26 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-10-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-08-10 | Body height | 170 cm | 8302-2 | S |
| 2026-08-10 | Body weight | 70.3 kg | 29463-7 | S |
| 2026-08-10 | Body mass index (BMI) [Ratio] | 24.3 kg/m2 | 39156-5 | S |
| 2026-08-10 | Systolic blood pressure | 132 mm[Hg] | 8480-6 | S |
| 2026-08-10 | Diastolic blood pressure | 82 mm[Hg] | 8462-4 | S |
| 2026-08-10 | Heart rate | 80 /min | 8867-4 | S |
| 2026-08-10 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-08-10 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-08-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-09-21 | Body height | 170 cm | 8302-2 | S |
| 2026-09-21 | Body weight | 70.4 kg | 29463-7 | S |
| 2026-09-21 | Body mass index (BMI) [Ratio] | 24.4 kg/m2 | 39156-5 | S |
| 2026-09-21 | Systolic blood pressure | 122 mm[Hg] | 8480-6 | S |
| 2026-09-21 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-09-21 | Heart rate | 72 /min | 8867-4 | S |
| 2026-09-21 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-09-21 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-09-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Occupation: college president, author, and frequent public speaker; works nine to five and most evenings, with heavy travel
- S Never smoker; drinks alcohol rarely
- S Eats on the road several days a week; high-sodium restaurant meals
- S Supports: spouse, adult children, and long-time colleagues who urged him to be seen
Functional status
- S Independent in all activities of daily living; tires more quickly and has cut back from full workdays
- S Finds he must prepare speeches in full and no longer trusts himself to speak impromptu
Mental status
- S Alert, oriented, articulate; reports slower concentration than before, without focal neurologic deficits
- S Mood steady; PHQ-9 below the depression threshold
Allergies and medications
Allergies
- S No known allergy
Medications
- S Amlodipine 10 mg oral tablet, one tablet by mouth daily
- S Losartan 50 mg oral tablet, one tablet by mouth daily
- S Losartan 100 mg oral tablet, one tablet by mouth daily
- S Dapagliflozin 10 mg oral tablet, one tablet by mouth daily
- S Chlorthalidone 25 mg oral tablet, one-half tablet (12.5 mg) by mouth daily
- S Atorvastatin 20 mg oral tablet, one tablet by mouth daily
Procedures and immunizations
Procedures
- S 12-lead electrocardiogram: sinus rhythm with left ventricular hypertrophy by voltage
- S Dilated funduscopic examination: arteriolar narrowing and arteriovenous nicking in both eyes; no hemorrhages, exudates, or papilledema
- S Renal ultrasound: both kidneys small (9.4 and 9.6 cm) and echogenic, without hydronephrosis
- S Transthoracic echocardiography: concentric left ventricular hypertrophy, ejection fraction 60 percent
Immunizations
- S 2025-10-20: Influenza vaccine, 2025-2026 season
- S 2026-05-11: Pneumococcal conjugate vaccine PCV20
- S 2026-05-11: Hepatitis B vaccine (HepB-CpG), dose 1 of 2
- S 2026-06-29: Hepatitis B vaccine (HepB-CpG), dose 2 of 2
- S 2019-09-16: Tdap vaccine
- S 2026-09-21: Influenza vaccine, 2026-2027 season
- S 2026-09-21: Recombinant zoster vaccine, dose 1 of 2
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D 1911: Assault in New York City with two large scalp lacerations and a torn ear; recovered without apparent sequelae (CLM-0005)
- D 1911: Chronic indigestion, worse when traveling; several days of treatment at the Battle Creek Sanitarium in 1911 (CLM-0005)
Family history
- D mother: Died in Malden, West Virginia, in 1876 (other accounts give 1874); cause not recorded in the cited source
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Lower blood pressure below 130/80 within two months | 2026-06-29 | completed | Blood pressure 128/80 on four medicines |
| Reach a standardized office systolic pressure below 120 when tolerated by the six-month review | 2026-10-26 | completed | Blood pressure 118/76 without dizziness |
| Reduce the urine albumin-creatinine ratio by at least 30 percent by the six-month review | 2026-10-26 | completed | UACR fell from 820 to 240 mg/g |
| Keep eGFR decline after starting therapy within 30 percent and stable thereafter | 2026-10-26 | completed | eGFR 36 at baseline, 30 on full therapy, 32 at six months |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Treat severe hypertension without acute target-organ damage as an outpatient: start losartan and amlodipine together, check home blood pressure twice daily, and go to the emergency department for chest pain, shortness of breath, weakness, confusion, or vision loss | completed | GL-HTN-2025 |
| Nephrology referral for eGFR below 60 with severely increased albuminuria (UACR above 300 mg/g) and stage 2 hypertension | completed | GL-KDIGO-CKD-2024, GL-CMID-2026 |
| Titrate losartan to the maximum tolerated dose and add an SGLT2 inhibitor for CKD with UACR of at least 200 mg/g; accept a creatinine rise of up to 30 percent | completed | GL-KDIGO-CKD-2024, GL-KDIGO-BP-2021 |
| Add chlorthalidone if blood pressure stays above target on two agents; avoid NSAIDs and review every medication dose for kidney function | completed | GL-KDIGO-BP-2021, GL-HTN-2025 |
| Check potassium and creatinine one to four weeks after each renin-angiotensin, SGLT2 inhibitor, or diuretic change; then eGFR and UACR about three times a year for G3b A3, hemoglobin at least yearly, and calcium, phosphate, and PTH every six to twelve months; recalculate the kidney failure risk yearly | completed | GL-CMID-2026, GL-KDIGO-CKD-2024 |
| Moderate-intensity statin for an adult aged 50 or older with eGFR below 60; no routine repeat LDL | completed | GL-KDIGO-CKD-2024, GL-CMID-2026 |
| Sodium below 2 g a day with a plan for meals while traveling; at least 150 minutes of activity a week | completed | GL-KDIGO-CKD-2024, GL-HTN-2025 |
| Annual dilated eye examination for hypertensive retinopathy; pneumococcal and hepatitis B vaccination for chronic kidney disease | completed | GL-CMID-2026 |
Planned encounters
- 2026-05-04 — Primary care visit for headaches, fatigue, and a very high blood pressure (ENC-001)
- 2026-05-11 — One-week blood pressure and kidney safety check with nephrology consultation (ENC-002)
- 2026-06-01 — Three-week check after losartan titration and dapagliflozin start (ENC-003)
- 2026-06-29 — Four-week check after adding chlorthalidone (ENC-004)
- 2026-08-10 — Same-day sick visit for low back pain (ENC-006, unscheduled)
- 2026-09-21 — Periodic adult preventive visit (ENC-007)
- 2026-10-26 — Six-month blood pressure and chronic kidney disease review (ENC-005)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Focused Visit (Follow-up)
- Progress note 05 — Sick Visit
- Progress note 06 — Preventive Visit
- Progress note 07 — Focused Visit (Care-plan review)
- Nephrology referral
- Nephrology consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Focused Visit (Follow-up) (XML)
- Progress note 05 — Sick Visit (XML)
- Progress note 06 — Preventive Visit (XML)
- Progress note 07 — Focused Visit (Care-plan review) (XML)
- Nephrology referral (XML)
- Nephrology consultation (XML)
Sources
| ID | Source | Publisher | Type |
|---|---|---|---|
| SRC-0001 | Booker T. Washington | U.S. National Park Service, Tuskegee Institute National Historic Site | government |
| SRC-0002 | Washington Timeline | U.S. National Park Service, Booker T. Washington National Monument | government |
| SRC-0003 | The Death of Booker T. Washington (site bulletin) | U.S. National Park Service, Booker T. Washington National Monument | government |
| SRC-0004 | Black B. The Strange Case of Booker T. Washington's Birthday. Contingent Magazine, April 5, 2021 | Contingent Magazine | other |
| SRC-0005 | Footprints: Women Who Influenced Booker T. Washington (news release) | U.S. National Park Service, Booker T. Washington National Monument | government |
| SRC-0006 | HISTMED Master Roster v3 | The Human Record project | other |
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the outpatient handling of severe hypertension and the five-visit titration schedule. |
| provenance review | not_started | NPS biography, timeline, death bulletin, and news release logged; the 2006 conference is known only through the NPS bulletin; the birth date is uncertain. |
| safe messaging review | not_started | The 1915 'racial characteristics' remark is flagged as sensitive and presented only with context; death recorded without graphic detail. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.